IBRX
ImmunityBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$8.93
+7.72%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$8.42
From 52W high−22.68%
Volume9.37M
Market cap$9.46B
P/E (TTM)—
P/S (TTM)57.1x
Div yield—
Key dataNov 4, 2026
Open
$8.42
From 52W high
−22.68%
Volume
9.37M
Market cap
$9.46B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−11.1x
P/E (TTM)
—
RSI (14)
45.0
MomentumView details →
1D Return
+7.72%
YTD Return
+319.19%
SummaryUpdated Jun 1, 2026
ImmunityBio, Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company founded in 2014 and headquartered in San Diego, California. The company went public in 2015 and focuses on developing innovative therapies and vaccines to treat cancers and infectious diseases. ImmunityBio operates at the cutting edge of immunotherapy and cell therapy, leveraging the body's immune system to fight diseases that have traditionally been difficult to treat.
Similar companies
Latest newsMore news →
ImmunityBio announced completion of the database lock for Cohort A of its ImmunityBio, Inc. registrational trial evaluating ANKTIVA plus BCG versus BCG alone in BCG-naïve non-muscle invasive bladder cancer.14d agoImmunityBio announced publication of long-term Phase 2/3 QUILT-3.032 study data reporting 84% cystectomy avoidance at three years and complete responses beyond 53 months for ANKTIVA plus BCG in patients with BCG-unresponsive NMIBC with CIS, with or without papillary tumors.19d agoThe U.S. Food and Drug Administration expanded the approved indication for ImmunityBio, Inc.’s ANKTIVA to include BCG-unresponsive non-muscle-invasive bladder cancer with papillary-only tumors.20d ago